Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.
Christoph FriedliNik KrajncHelly N HammerStefanie MartiTobias ZrzavyMaria E EvangelopoulosIoanna KapsaliPaulus RommerThomas BergerAndrew ChanGabriel BstehRobert HoepnerPublished in: Journal of central nervous system disease (2024)
Different effects on lymphocyte subpopulations appear to be present in pwMS after treatment initiation with different anti-CD20 mAbs. Further studies are needed to determine potential effects on anti-CD20 treatment efficacy as well as treatment associated risks such as failed vaccinations and infections.